SUPPLEMENTAL TABLE 1. Quantitative qRT-PCR primer list.

SUPPLEMENTAL FIGURE 1. eHsp90 mediated migration requires LRP1. *A*, Representative results of a scratch wounding assay with PC3 following treatment with NPGA (1 uM) or either of two different eHsp90 antibodies (SPA-830, Ab1; SPS-771, Ab2). *B*, Immunoblot validation of LRP1 shRNA knockdown in DU145 cells. Representative images of cell motility from a wounding assay with scrambled (scr) shRNA or shLRP1 in DU145 prostate cancer cells. Magnification is 100x. Asterisks (*) indicate significance $p \leq 0.05$.

SUPPLEMENTAL FIGURE 2. eHsp90 promotes LRP1 mediated motility and ERK phosphorylation. *A*, Immunoblot analysis of LRP1 and indicated EMT effectors in ARCaPE/ARCaPM and M12/P69 cell pairs. *B*, *C*, Wounding assay in ARCaPE/P69 following a 3 day pretreatment with eHsp90 protein, and in ARCaPM/M12 with NPGA treatment for 20 h. *D*, Immunoblot validation of LRP1 expression in ARCaPE shLRP1 cells, and wounding assay to evaluate the effects upon eHsp90 directed cell motility. Magnification is 100x. *E*, Time dependent analysis of MEK/ERK activation from ARCaPE cells treated with 3 ug/ml eHsp90.

SUPPLEMENTAL FIGURE 3. eHsp90 regulates the localization of junctional proteins and cell morphology. *A*, Confocal microscopy was utilized to evaluate E-cadherin and ZO-1 cellular localization in P69 control (lac Z transduced) and P69-eHsp90 modified cells. *B*, Evaluation of the effects of eHsp90 inhibition (5 day NPGA treatment) upon E-cadherin and ZO1 membrane localization in ARCaPM and M12 prostate mesenchymal cell lines. Scale bar is 50 um.

SUPPLEMENTAL FIGURE 4. Proteolytic activity and ERK signaling is required for eHsp90 mediated cell migration. Wounding assay using ARCaPE-eHsp90 prostate cancer cells pretreated with NPGA (1 uM), GM6001 (1 uM), MMP2/9 inhibitor (SB-3CT, 1 uM) MMP3 inhibitor (inhibitor IV, 5 uM) and ERK inhibitor (UO126, 10uM) for three days. Magnification is 100x.

Name	Accession#		Sequence
CDH1	NM_004360	Sense	TGGGCCAGGAAATCACATCCTACA
		Antisense	TTGGCAGTGTCTCTCCAAATCCGA
SNAI1	NM_005985	Sense	TTTCTGGTTCTGTGTCCTCTGCCT
		Antisense	TTCCCAGTGAGTCTGTCAGCCTTT
SNAI2	NM_003068	Sense	TTTCTGGGCTGGCCAAACATAAGC
		Antisense	ACACAAGGTAATGTGTGGGTCCGA
ZEB1	NM_030751	Sense	ATGCACAACCAAGTGCAGAAGAGC
		Antisense	TTGCCTGGTTCAGGAGAAGATGGT
ZEB2	NM_014795	Sense	ATATGGTGACACACAAGCCAGGGA
		Antisense	GTTTCTTGCAGTTTGGGCACTCGT
MMP2	NM_004530	Sense	AGAAGGATGGCAAGTACGGCTTCT
		Antisense	AGTGGTGCAGCTGTCATAGGATGT
MMP3	NM_002422	Sense	AGGTGTGGAGTTCCTGATGTTGGT
		Antisense	TACAGCCTGGAGAATGTGAGTGGA
MMP9	NM_004994	Sense	ATTTCTGCCAGGACCGCTTCTACT
		Antisense	CAGTTTGTATCCGGCAAACTGGCT
GAPDH	NM_002046	Sense	TCGACAGTCAGCCGCATCTTCTTT
		Antisense	ACCAAATCCGTTGACTCCGACCTT

Table S1


A
Untreated
NPGA
Hsp90 Ab1
Hsp90 Ab2
PC3
0 hr
16 h
16 h
16 h
16 h
B
LRP1
Tubulin
DU145
Control
Scr shRNA
shLRP1
C
Scr shRNA
shLRP1
0h
16h
0h
16h
Untreated
NPGA
DU145

Fig. S1


A
ARCaPM
ARCaPE
M12
P69
LRP1
E-Cad
Vimentin
Twist
Snail
Slug
Tubulin
B
Untreated
Hsp90
Untreated
NPGA
0h
20h
20h
0h
20h
20h
ARCaPE
ARCaPM
C
Untreated
Hsp90
Untreated
NPGA
0h
20h
20h
0h
20h
20h
P69
M12
D
ARCaPE
LRP1
Tubulin
Control
Scr shRNA
shLRP1
Scr shRNA
shLRP1
0h
16h
0h
16h
Untreated
Hsp90
ARCaPE
E
Hsp90 (min) 0 5 10 15 20 30
P-MEK
MEK
P-ERK
ERK
ARCaPE

Fig. S2


A
P69 LacZ
P69-eHsp90
E-cad/Topro
ZO1/Topro
B
Untreated
5d NPGA
Untreated
5d NPGA
E-cad/Topro
ZO1/Topro
ARCaPM
M12

Fig. S3


ARCaPE-LacZ
Untreated
0h
20h
ARCaPE-eHsp90
Untreated
NPGA
GM6001
MMP2/9 In
MMP3 In
UO126
0h
20h
20h
20h
20h
20h
20h

Fig. S4